Replies to post #25486 on Radient Pharmaceuticals Corporation fka RXPC

[GetSeriousOK]

Everyone now "has all rights to use DR-70 at no cost to them" because DR-70 is now off patent.

I don't know whether Gartner is an Executive VP at Provista or what that title even means but none of that matters. Who cares why Gartner started up GCDx or why he stepped down as Provista CEO or why Provista dropped the lung cancer test? The fact is:

DR-70 is currently off patent. Anyone can manufacture and sell DR-70 now without paying any royalties or fees or payments to Radient.


That one fact kills the Radient takeover rumor. Or at least it should -- the Radient takeover rumor seems to be immortal. Facts don't kill it and logic doesn't kill it.

What silver bullet will kill the Radient Takeover Rumor? I am fascinated by this. The patent rejection should have been enough. Add all these bullets:

-> Gartner states that he has no professional or personal relationship with Radient.

-> MacLellan states that he left all his management positions with Radient in April and has not communicated with them since.

-> Provista states that none of their diagnostics use DR-70.

-> GCDx is actively moving forward with their business plan to sell DR-70 without any merger or takeover.

-> UNI is manufacturing and selling DR-70 in Asia while Radient lies dormant.

-> Radient management said in their last 8k that Radient is insolvent (after three years of alleged reverse merger activity).

That's a lot of silver bullets, yet the Takeover Rumor lives on. Fascinating.

[GetSeriousOK]

Gartner doesn't work for Provista, IMO.

The only place there is a reference to Gartner still holding a position at Provista is a LinkedIn page. We've proven several times that LinkedIn is not 100% accurate. And what is an Executive VP anyway? Gartner is not listed on any of Provista's recent filings.

If Gartner didn't get the IP by paying $6000 to Radient, he got it from Provista when he resigned from Provista and created GCDx. However he got the IP, he has it now, and silly or not, Gartner is moving forward with his plans to sell DR-70 through GCDx.

Starting GCDx didn't cost much money. I haven't seen any evidence that GCDx has spent much money on anything. Yet. Submitting a 510(k) would be a significant expense. I will be surprised if/when GCDx gets the money for that.

Trademarks don't matter. Trademarks only stop someone else from using that name or picture or slogan. Who cares what he calls it or why he abandoned the first name (it was because they rejected the application, wolfie, you posted the link yourself in the past). Bottom line, the Trademark for Gartner's test is the least significant thing here. The patent is all that matters. Without a patent, Radient has no assets and can never rise from the ashes, IMO.

[GetSeriousOK]

If Gartner is still an Executive VP at Provista, why isn't he listed on Provista's "Executive Management" page?

http://provistadx.com/ProvistaDx-Management.html

I think LinkedIn is a horrible source for DD. I don't think Gartner has any position at Provista now. I also think he is telling the truth when he says he has no personal or business relationship with Radient Pharmaceuticals.